Clinical opinion: The biologic and pharmacologic principles of estrogen therapy for symptomatic menopause

MedGenMed Medscape General Medicine

Volumn 8, Issue 1, 2006, Pages

  Notelovitz, Morris ^a,b  

^a Department of Adult Women's Health and Medicine ^*

^b International Menopause Society

Author keywords

[No Author keywords available]

Indexed keywords

CENTCHROMAN; CONJUGATED ESTROGEN; EQUILIN; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE SULFATE; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; ATROPHY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSPORT; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; HEALTH CARE NEED; HOT FLUSH; HUMAN; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; META ANALYSIS; PATHOGENESIS; PHARMACODYNAMICS; POSTMENOPAUSE; PRESCRIPTION; QUALITY OF LIFE; STEROIDOGENESIS; SYMPTOM; SYSTEMATIC REVIEW; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER; AGED; DRUG EFFECT; FEMALE; MENOPAUSE; MIDDLE AGED; REVIEW;

AGED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED;

EID: 33645282233     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346:340-352. Abstract
2. Weiss G, Skurnick JH, Goldsmith LT, et al. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA. 2004;292:2991-2996. Abstract
3. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712. Abstract
4. Notelovitz M. Age-adjusted long-term estrogen therapy: biologic and pharmacologic principles for clinical practice. Medscape General Medicine. 2006.
5. Nilsson S, Makela S, Treuter E, et al. Mechanism of estrogen action. Physiol Rev. 2001;81:1535-1565. Abstract
6. Levin ER Cellular functions of plasma membrane estrogen receptors. Steroids. 2002;67:471-475. Abstract
7. Clemmons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276-285. Abstract
8. Labrie F, Belanger A, Luu-The V, et al. DHEA and intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids. 1998;63:322-328. Abstract
9. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27. Abstract
10. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol. 2001;184:255-263. Abstract
11. Stanczyk F. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol. 2001;15(suppl 4):17-25.
12. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med. 1998;217:6-16. Abstract
13. Slater CC, Hodis HN, Mack WJ, et al. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause. 2001;8:200-203. Abstract
14. Buster JE. Estrogen kinetics for clinicians. In: Sciarra JJ, ed. Gynecology and Obstetrics: Endocrinology, Infertility, Genetics. Vol. 5. Philadelphia, Pa: JB Lippincott; 1994:1-16.
15. Roberts KD, Rochefort JG, Bleu G, Chapdelaine A. Plasma estrone sulfate levels in postmenopausal women. Steroids. 1980;35:179-187. Abstract
16. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. Horm Metab Res. 1998;30:598-600. Abstract
17. Nachtigall LE, Raju U, Banerjee S, et al. Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol and estrone levels. Menopause. 2000;7:243-250. Abstract
18. Mandel FP, Geola FL, Lu. JK, et al. Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol. 1982;59:673-679. Abstract
19. Archer DF, Fischer LA, Rich D, et al. Estrace vs Premarin for treatment of menopausal symptoms: dosage comparison study. Adv Ther. 1992;9:21-31.
20. Lobo RA, Nguyen HN, Eggena P, Brenner PF. Biologic effects of equilin sulfate in postmenopausal women. Fertil Steril. 1988;49:234-238. Abstract
21. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004; 11:356-367. Abstract
22. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 2000;102:2687-2693. Abstract
23. Oldenhave A, Jaszmann IJ, Haspels AA, et al. Impact of climacteric on well-being. A survey based on 5313 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772-780. Abstract
24. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol. 1999;180:312-316.
25. Steams V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet. 2002;360:1851-1861. Abstract
26. Overlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas. 2002;41:69-77. Abstract
27. Casson PR, Elkind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol. 1997;90:995-998. Abstract
28. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-1620. Abstract
29. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17beta estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731. Abstract
30. Utian WH, Shoupe D, Bachmann GA, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065-1079. Abstract
31. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard and high dosages of an estradiol transport system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol. 1999;181:71-79. Abstract
32. Gangar K, Cust M, Whitehead MJ. Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. BMJ. 1989;299:601-602.
33. Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy. Menopause. 2000;7:140-142. Abstract
34. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol. 1989; 160:176-181. Abstract
35. Fantl JA, Wyman JF, Anderson RL, et al. Postmenopausal urinary incontinence: comparison between non-estrogen supplemented and estrogen supplemented women. Obstet Gynecol. 1988;71:823-828. Abstract
36. Brizzolara S, Killeen J, Severino R. Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol. 1999;94:700-703. Abstract
37. Bachmann G, Notelovitz M, Nachtigall L, Bergerson L. A comparative study of low-dose estradiol vaginal ring and conjugated estrogen cream for postmenopausal urogenital atrophy. Prim Care Update Ob/Gyns. 1997;4:109-115.
38. Rioux JE, Devlin MC, Gelfand MM, et al. 17beta estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7:156-161. Abstract
39. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556-562. Abstract
40. Simunic V, Banovic J, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82:187-197. Abstract
41. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Committee. Obstet Gynecol. 1994;83:12-18. Abstract
42. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol. 2001;97:116-120. Abstract
43. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of estrogen supplementation on postmenopausal urinary stress incontinence: a double blind placebo controlled trial. Br J Obstet Gynaecol. 1999; 106:711-718. Abstract
44. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol. 2004;103:254-260. Abstract
45. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol. 2002;187:521-527. Abstract
46. Goldstein SR. An update on non-uterine gynecological effects of raloxifene. Eur J Cancer. 2002;38(suppl 6):S65-S66. Abstract
47. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta estradiol. Menopause. 2000;7:310-317. Abstract
48. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health related quality of life. N Engl J Med. 2003;348:1839-1854. Abstract
49. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003;44:157-163. Abstract
50. Lenfant C. Clinical cesearch to clinical practice - lost in translation? N Engl J Med. 2003;349:868-874.
51. Notelovitz M. The clinical practice impact of the Women's Health Initiative: political vs biologic correctness. Maturitas. 2003;44:3-9. Abstract